Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q38484053)
Watch
English
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
scientific article published on May 2015
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
review article
1 reference
stated in
Europe PubMed Central
title
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
main subject
lung cancer
1 reference
based on heuristic
inferred from title
author
Ryohei Katayama
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
Christine M. Lovly
series ordinal
2
object named as
Christine M Lovly
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
author name string
Alice T Shaw
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
language of work or name
English
0 references
publication date
1 May 2015
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
published in
Clinical Cancer Research
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
volume
21
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
issue
10
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
page(s)
2227-2235
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
cites work
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Q27690215
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Ceritinib in ALK-rearranged non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
RET, ROS1 and ALK fusions in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Crizotinib in anaplastic large-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
A mouse model for EML4-ALK-positive lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Activation of tyrosine kinases by mutation of the gatekeeper threonine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Identification of ALK as a major familial neuroblastoma predisposition gene
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
6 September 2017
Oncogenic mutations of ALK kinase in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
14 September 2017
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
14 September 2017
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
23 June 2018
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
23 June 2018
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
23 June 2018
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
23 June 2018
Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
23 June 2018
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Anchored multiplex PCR for targeted next-generation sequencing
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Taking aim at ALK across the blood-brain barrier
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
A novel KIF5B-ALK variant in nonsmall cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Reversal of multidrug resistance by a novel quinoline derivative, MS-209.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
31 August 2018
Immune checkpoint modulation for non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4435823
retrieved
1 October 2018
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25979929
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25979929
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/1078-0432.CCR-14-2791
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
PMC publication ID
4435823
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
PubMed publication ID
25979929
1 reference
stated in
Europe PubMed Central
PMC publication ID
4435823
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25979929%20AND%20SRC:MED&resulttype=core&format=json
retrieved
8 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
